Publications

Publications

Filter Results: (617) Arrow Down
Filter Results: (617) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 12 of 617 Results →
  • January 2009
  • Case

When Supply is of Public Interest: Roche & Tamiflu

The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
Related
  • Profile

Avi Kremer

millions of dollars into research, and removed critical barriers to the development of treatments. “Our focus was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed in 2004, just weeks into his first year at... View Details
Keywords: Health Care; Entrepreneurship

    Srikant M. Datar

    Srikant M. Datar became the eleventh dean of Harvard Business School on 1 January 2021. During his tenure as a faculty member, he served as Senior Associate Dean for University Affairs (including Faculty Chair of the Harvard Innovation Lab), for Research, for... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

      Youngme Moon

      Youngme Moon is the Donald K. David Professor of Business at Harvard Business School. Professor Moon's research sits at the intersection of brand strategy and culture, with a particular focus on the emergent AI economy. She is the author of the bestselling book, View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

        Joshua D. Margolis

        Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • 31 Jan 2007
        • Working Paper Summaries

        Behavioral Decision Research, Legislation, and Society: Three Cases

        Keywords: by Max H. Bazerman
        • 14 Aug 2007
        • First Look

        First Look: August 14, 2007

        managing a master limited partnership with over $35 billion in infrastructure assets. In the summer of 2006, Richard Kinder, the founder and chairman of Kinder Morgan, led a consortium of buyers to take the company private. The... View Details
        Keywords: Martha Lagace
        • September–October 2020
        • Article

        Social-Impact Efforts That Create Real Value

        By: George Serafeim
        Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create... View Details
        Keywords: Sustainability; Sustainability Management; ESG; ESG (Environmental, Social, Governance) Performance; ESG Disclosure; ESG Disclosure Metrics; ESG Ratings; ESG Reporting; Social Impact; Impact Measurement; Social Innovation; Purpose; Corporate Purpose; Corporate Social Responsibility; Strategy; Social Enterprise; Society; Accounting; Investment; Environmental Sustainability; Climate Change; Corporate Strategy; Mission and Purpose; Corporate Social Responsibility and Impact; Financial Services Industry; Chemical Industry; Technology Industry; Consumer Products Industry; Pharmaceutical Industry; North America; Europe; Japan; Australia
        Related
        • October 2021 (Revised October 2022)
        • Case

        The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

        By: Suraj Srinivasan and Li-Kuan Ni
        In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details
        Keywords: Opioids; Drug; Investors; Shareholder Activism; Investment Activism; Executive Compensation; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Legal Liability; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
        Related
        • 01 Aug 2023
        • Cold Call Podcast

        Can Business Transform Primary Health Care Across Africa?

        Keywords: Re: Regina E. Herzlinger; Pharmaceutical; Pharmaceutical
        • Web

        Strategy - Doctoral

        Strategy The doctoral program in Strategy encourages students to pursue multi-disciplinary research that utilizes multiple methodologies—quantitative, as well as qualitative—to study how companies and industries around the world develop... View Details

          Robert S. Huckman

          Robert Huckman is the Albert J. Weatherhead III Professor of Business Administration at Harvard Business School, the Howard Cox Faculty Chair of the HBS Healthcare Initiative, and the Unit Head for View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

            Gary P. Pisano

            Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • February 2024
            • Case

            Compass Pathways: Pioneering Psychedelic Treatment

            By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
            This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
            Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
            Related
            • 15 Jan 2008
            • First Look

            First Look: January 15, 2008

            industry research to inform investment decisions. Provides detailed information about the recommended resources available for this type of research, focusing primarily on what is available from Harvard Business School's Baker Library. Focusing on how View Details
            Keywords: Martha Lagace

              Ranjay Gulati

              Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. He is an expert on leadership, strategy, and organizational issues... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
              • June 2004 (Revised June 2006)
              • Supplement

              Vertex Pharmaceuticals: R&D Portfolio Management (A)

              By: Gary P. Pisano, Lee Fleming and Eli Strick
              Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
              Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry
              Related
              • Web

              Hiring Organizations

              S.p.A. Anomaly Capital Management Antelope Anterra Capital Anthos Capital Anthropic Antora Energy Apeiron Labs Apollo Global Management Inc. Apple Inc. Applied Intuition Applied Ventures LLC Aquamarine Capital Ara Partners Arado Arcellx, Inc. Archer Daniels Midland... View Details
              • 05 Sep 2023
              • Book

              Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

              recessionary headwinds, the real innovation that can come out of learning from intelligent failures may be what companies most need today. As Edmondson put it, “It’s natural to hunker down and imply that failure is to be avoided in tough... View Details
              Keywords: by Michael Blanding
              • 21 Apr 2009
              • First Look

              First Look: April 21, 2009

                Working PapersHow Firms Respond to Being Rated (revised) Authors:Aaron K. Chatterji and Michael W. Toffel Abstract While many rating systems seek to help buyers overcome information asymmetries when making purchasing decisions, we investigate how these ratings also... View Details
              Keywords: Martha Lagace